397 related articles for article (PubMed ID: 35322860)
1. Use of conditional reprogramming cell, patient derived xenograft and organoid for drug screening for individualized prostate cancer therapy: Current and future perspectives (Review).
Cao J; Chan WC; Chow MSS
Int J Oncol; 2022 May; 60(5):. PubMed ID: 35322860
[TBL] [Abstract][Full Text] [Related]
2. A synopsis of prostate organoid methodologies, applications, and limitations.
Gleave AM; Ci X; Lin D; Wang Y
Prostate; 2020 May; 80(6):518-526. PubMed ID: 32084293
[TBL] [Abstract][Full Text] [Related]
3. A PDX/Organoid Biobank of Advanced Prostate Cancers Captures Genomic and Phenotypic Heterogeneity for Disease Modeling and Therapeutic Screening.
Beshiri ML; Tice CM; Tran C; Nguyen HM; Sowalsky AG; Agarwal S; Jansson KH; Yang Q; McGowen KM; Yin J; Alilin AN; Karzai FH; Dahut WL; Corey E; Kelly K
Clin Cancer Res; 2018 Sep; 24(17):4332-4345. PubMed ID: 29748182
[No Abstract] [Full Text] [Related]
4. Patient derived organoids in prostate cancer: improving therapeutic efficacy in precision medicine.
Pamarthy S; Sabaawy HE
Mol Cancer; 2021 Sep; 20(1):125. PubMed ID: 34587953
[TBL] [Abstract][Full Text] [Related]
5. High-Throughput Imaging Assay for Drug Screening of 3D Prostate Cancer Organoids.
Choo N; Ramm S; Luu J; Winter JM; Selth LA; Dwyer AR; Frydenberg M; Grummet J; Sandhu S; Hickey TE; Tilley WD; Taylor RA; Risbridger GP; Lawrence MG; Simpson KJ
SLAS Discov; 2021 Oct; 26(9):1107-1124. PubMed ID: 34111999
[TBL] [Abstract][Full Text] [Related]
6. Challenges, applications and future directions of precision medicine in prostate cancer - the role of organoids and patient-derived xenografts.
Joshi A; Roberts MJ; Alinezhad S; Williams ED; Vela I
BJU Int; 2020 Jul; 126(1):65-72. PubMed ID: 32383524
[TBL] [Abstract][Full Text] [Related]
7. Viability Analysis and High-Content Live-Cell Imaging for Drug Testing in Prostate Cancer Xenograft-Derived Organoids.
Van Hemelryk A; Erkens-Schulze S; Lim L; de Ridder CMA; Stuurman DC; Jenster GW; van Royen ME; van Weerden WM
Cells; 2023 May; 12(10):. PubMed ID: 37408211
[TBL] [Abstract][Full Text] [Related]
8. Conditional Reprogramming for Patient-Derived Cancer Models and Next-Generation Living Biobanks.
Palechor-Ceron N; Krawczyk E; Dakic A; Simic V; Yuan H; Blancato J; Wang W; Hubbard F; Zheng YL; Dan H; Strome S; Cullen K; Davidson B; Deeken JF; Choudhury S; Ahn PH; Agarwal S; Zhou X; Schlegel R; Furth PA; Pan CX; Liu X
Cells; 2019 Oct; 8(11):. PubMed ID: 31717887
[TBL] [Abstract][Full Text] [Related]
9. Introduction of Androgen Receptor Targeting shRNA Inhibits Tumor Growth in Patient-Derived Prostate Cancer Xenografts.
Thomas PB; Alinezhad S; Joshi A; Sweeney K; Tse BWC; Tevz G; McPherson S; Nelson CC; Williams ED; Vela I
Curr Oncol; 2023 Oct; 30(11):9437-9447. PubMed ID: 37999103
[TBL] [Abstract][Full Text] [Related]
10. Organoid development in cancer genome discovery.
Gao D; Chen Y
Curr Opin Genet Dev; 2015 Feb; 30():42-8. PubMed ID: 25796043
[TBL] [Abstract][Full Text] [Related]
11. Establishment of PDX-derived salivary adenoid cystic carcinoma cell lines using organoid culture method.
Takada K; Aizawa Y; Sano D; Okuda R; Sekine K; Ueno Y; Yamanaka S; Aoyama J; Sato K; Kuwahara T; Hatano T; Takahashi H; Arai Y; Nishimura G; Taniguchi H; Oridate N
Int J Cancer; 2021 Jan; 148(1):193-202. PubMed ID: 32984947
[TBL] [Abstract][Full Text] [Related]
12. Personalized Cancer Medicine: An Organoid Approach.
Aboulkheyr Es H; Montazeri L; Aref AR; Vosough M; Baharvand H
Trends Biotechnol; 2018 Apr; 36(4):358-371. PubMed ID: 29366522
[TBL] [Abstract][Full Text] [Related]
13. Advantages and limitations of 3D organoids and ex vivo tumor tissue culture in personalized medicine for prostate cancer.
Mickova A; Morong M; Levková M; Kurfúrstová D; Kharaishvili G; Überall I; Student V; Student V; Drapela S; Soucek K; Bouchal J
Klin Onkol; 2022; 35(6):473-481. PubMed ID: 36513514
[TBL] [Abstract][Full Text] [Related]
14. A patient-derived explant (PDE) model of hormone-dependent cancer.
Centenera MM; Hickey TE; Jindal S; Ryan NK; Ravindranathan P; Mohammed H; Robinson JL; Schiewer MJ; Ma S; Kapur P; Sutherland PD; Hoffmann CE; Roehrborn CG; Gomella LG; Carroll JS; Birrell SN; Knudsen KE; Raj GV; Butler LM; Tilley WD
Mol Oncol; 2018 Sep; 12(9):1608-1622. PubMed ID: 30117261
[TBL] [Abstract][Full Text] [Related]
15. Establishment and Analysis of Three-Dimensional (3D) Organoids Derived from Patient Prostate Cancer Bone Metastasis Specimens and their Xenografts.
Lee S; Burner DN; Mendoza TR; Muldong MT; Arreola C; Wu CN; Cacalano NA; Kulidjian AA; Kane CJ; Jamieson CAM
J Vis Exp; 2020 Feb; (156):. PubMed ID: 32065165
[TBL] [Abstract][Full Text] [Related]
16. New Therapeutic Perspectives in Prostate Cancer: Patient-Derived Organoids and Patient-Derived Xenograft Models in Precision Medicine.
Rago V; Perri A; Di Agostino S
Biomedicines; 2023 Oct; 11(10):. PubMed ID: 37893116
[TBL] [Abstract][Full Text] [Related]
17. A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology.
Guillen KP; Fujita M; Butterfield AJ; Scherer SD; Bailey MH; Chu Z; DeRose YS; Zhao L; Cortes-Sanchez E; Yang CH; Toner J; Wang G; Qiao Y; Huang X; Greenland JA; Vahrenkamp JM; Lum DH; Factor RE; Nelson EW; Matsen CB; Poretta JM; Rosenthal R; Beck AC; Buys SS; Vaklavas C; Ward JH; Jensen RL; Jones KB; Li Z; Oesterreich S; Dobrolecki LE; Pathi SS; Woo XY; Berrett KC; Wadsworth ME; Chuang JH; Lewis MT; Marth GT; Gertz J; Varley KE; Welm BE; Welm AL
Nat Cancer; 2022 Feb; 3(2):232-250. PubMed ID: 35221336
[TBL] [Abstract][Full Text] [Related]
18. Engineering Prostate Cancer from Induced Pluripotent Stem Cells-New Opportunities to Develop Preclinical Tools in Prostate and Prostate Cancer Studies.
Hepburn AC; Sims CHC; Buskin A; Heer R
Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32019175
[TBL] [Abstract][Full Text] [Related]
19. Establishment of patient-derived cancer organoids for drug-screening applications.
Driehuis E; Kretzschmar K; Clevers H
Nat Protoc; 2020 Oct; 15(10):3380-3409. PubMed ID: 32929210
[TBL] [Abstract][Full Text] [Related]
20. Circulating tumor cell-derived organoids: Current challenges and promises in medical research and precision medicine.
Praharaj PP; Bhutia SK; Nagrath S; Bitting RL; Deep G
Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):117-127. PubMed ID: 29360544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
